SCHEMBL1521601

SCHEMBL1521601

CNc1nc(SC)ncc1CNc1cc([N+](=O)[O-])c(F)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 3/20 0.34
POLB P06746 3/20 0.34
GALR2 O43603 1/20 0.34
PRKCQ Q04759 8/20 0.33
THRB P10828 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CDK1 P06493 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
PIM1 P11309 1/20 0.33
CYP2C9 P11712 1/20 0.33
CDK2 P24941 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521515 0.89 KMT2A (0.39) MAPTALDH1A1MAPK1KMT2AL3MBTL1
SCHEMBL1521507 0.83 GAA (0.47) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL4551507 0.83 KMT2A (0.32) KMT2AMEN1LMNAPOLBGALR2
SCHEMBL1521498 0.80 MAPT (0.43) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL3578831 0.75 KMT2A (0.39) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL1521438 0.74 GAA (0.46) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL23649026 0.73 DHFR (0.40) MAPTKMT2AMEN1LMNATHRB
SCHEMBL30346294 0.72 KMT2A (0.43) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL26090919 0.72 KMT2A (0.43) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL6619029 0.72 NPC1 (0.44) MAPTALDH1A1KMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
CN-101516379-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-08-26 CN disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 MAPT 1608/4885ALDH1A1 1389/4885MAPK1 93/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPT 1608/4885ALDH1A1 1389/4885MAPK1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.